Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M

Axogen, Inc.

2026-Q1 EPS reported -$0.38 revenue$61,457,000

Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
GAAP net loss $19.6M ($0.38/share); adjusted net income $4.1M ($0.07/share) vs adjusted net loss $0.9M in Q1 2025.
Raises full-year 2026 revenue guidance to at least 20% growth or $270M; expects gross margin 74%-76% and positive free cash flow.
Closed upsized public offering netting $133.3M; used $69.7M to repay Oberland loan; cash & investments rose to $103.6M.
Received positive coverage decisions from Cigna and Elevance Health; CMS new Level 3 Nerve Procedure Code boosts Avance reimbursement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Axogen, Inc. reported first quarter ended March 31, 2026 results: revenue $61.5 million, net income Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $61.5 million
Net income: Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share
EPS: $0.38 per share
Guidance: raised
Result: reported results

Exact text from the filing

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results • First quarter 2026 revenue was $61.5 million

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-26-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.